Group 1 - The core point of the news is that 乐心医疗 (Loxin Medical) experienced a decline of 5.18% in its stock price, reaching 15.19 yuan per share, with a trading volume of 115 million yuan and a turnover rate of 4.58%, resulting in a total market capitalization of 3.321 billion yuan [1] - 乐心医疗 is primarily engaged in the research, production, and sales of home medical health electronic products, with its main business revenue composition being: home medical products 66.29%, home health products 24.17%, others 7.55%, and smart wearables 1.99% [1] - The company is located in Zhongshan City, Guangdong Province, and was established on July 18, 2002, with its listing date on November 16, 2016 [1] Group 2 - From the perspective of the top ten circulating shareholders, 永赢基金 (Yongying Fund) has one fund that ranks among the top ten shareholders of 乐心医疗, while the Medical Device ETF (159883) entered the top ten circulating shareholders in the third quarter, holding 936,200 shares, which accounts for 0.58% of the circulating shares [2] - The Medical Device ETF (159883) was established on April 22, 2021, with a latest scale of 4.73 billion yuan, and has achieved a return of 11.25% this year, ranking 708 out of 5,531 in its category [2] - The fund manager of the Medical Device ETF is 储可凡 (Chu Kefa), who has a total fund asset scale of 6.282 billion yuan, with the best fund return during his tenure being 103.17% and the worst being -30.27% [3]

Group 1 - The core viewpoint of the news is that 乐心医疗 (Loxin Medical) has experienced a significant stock price increase, rising 5.15% to 16.14 CNY per share, with a total market capitalization of 3.528 billion CNY and a cumulative increase of 10.19% over three days [1] - 乐心医疗 specializes in home health management, focusing on the research, production, and sales of home medical health electronic products, as well as the development and operation of the 乐心智能健康云平台 (Loxin Smart Health Cloud Platform) [1] - The revenue composition of 乐心医疗 includes 66.29% from home medical products, 24.17% from home health products, 7.55% from other sources, and 1.99% from smart wearables [1] Group 2 - The top circulating shareholder data indicates that a fund under 永赢基金 (Yongying Fund) is among the top shareholders of 乐心医疗, with the 医疗器械ETF (Medical Device ETF) newly entering the top shareholders list, holding 936,200 shares, which is 0.58% of the circulating shares [2] - The 医疗器械ETF (159883) has a total scale of 4.73 billion CNY and has achieved a year-to-date return of 11.54%, ranking 820 out of 5,517 in its category [2] - The fund manager of the 医疗器械ETF is 储可凡 (Chu Kefa), who has a total fund asset scale of 6.282 billion CNY and has achieved a best fund return of 103.17% during his tenure [3]

Group 1 - The core viewpoint of the news is that 乐心医疗 (Loxin Medical) experienced a stock price increase of 5.09%, reaching 15.27 CNY per share, with a trading volume of 1.03 billion CNY and a turnover rate of 4.23%, resulting in a total market capitalization of 33.38 billion CNY [1] - 乐心医疗 is based in Zhongshan, Guangdong Province, and was established on July 18, 2002. It was listed on November 16, 2016. The company specializes in the research, production, and sales of home healthcare electronic products, as well as the development and operation of the Loxin Smart Health Cloud platform [1] - The revenue composition of 乐心医疗 includes: 66.29% from home medical products, 24.17% from home health products, 7.55% from other sources, and 1.99% from smart wearables [1] Group 2 - From the perspective of the top ten circulating shareholders of 乐心医疗, a fund under 永赢基金 ranks among the top shareholders. The Medical Device ETF (159883) entered the top ten circulating shareholders in the third quarter, holding 936,200 shares, which accounts for 0.58% of the circulating shares, with an estimated floating profit of approximately 692,800 CNY [2] - The Medical Device ETF (159883) was established on April 22, 2021, with a current scale of 4.73 billion CNY. Year-to-date, it has achieved a return of 9.24%, ranking 717 out of 5,579 in its category; over the past year, it has returned 15.92%, ranking 3,629 out of 4,202; since inception, it has incurred a loss of 46.7% [2]

格隆汇1月9日丨乐心医疗(300562.SZ)公布，截至2026年1月8日，公司"增益1号"员工持股计划已从二级 市场通过集中竞价方式累计买入公司股票587,800股，占公司目前总股本（截至2025年12月31日，公司 总股本为218,613,688股）的0.27%，成交金额为8,095,822.00元（不含交易费用），成交均价为13.77元/ 股。公司"增益1号"员工持股计划已完成股票购买，累计购买数量和成交金额均未超过公司股东会审议 通过的上限。本员工持股计划所获标的股票的锁定期为12个月，自公司公告最后一笔标的股票购买完成 之日起算，即本员工持股计划的锁定期为2026年1月9日至2027年1月9日，锁定期届满后一次性解锁，解 锁比例为100%。 ...

乐心医疗 2026 年公告 证券代码：300562 证券简称：乐心医疗 公告编号：2026-003 广东乐心医疗电子股份有限公司 关于增益1号员工持股计划完成股票购买暨实施进展的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 广东乐心医疗电子股份有限公司（以下简称"公司"）分别于 2025 年 9 月 9 日、2025 年 9 月 29 日召开第五届董事会第五次会议与 2025 年第三次临时股东 会审议通过了《关于<"增益 1 号"员工持股计划（草案）>及其摘要的议案》 等议案，同意公司通过二级市场购入标的股票的方式实施"增益 1 号"员工持股 计划（以下简称"本员工持股计划"）。具体详见公司分别于 2025 年 9 月 11 日、 2025 年 9 月 29 日披露在巨潮资讯网（www.cninfo.com.cn）的相关内容。 公司根据《关于上市公司实施员工持股计划试点的指导意见（2025 年修订）》 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作 （2025 年修订）》等相关规定积极推进本员工持股计划的实施，现将公司本员 工 ...

针对上述提问，乐心医疗回应称："投资者您好！截至2025年12月31日，公司股东总户数为23345户，感 谢您的关注，祝您投资顺利！" 声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 来源：市场资讯 有投资者在互动平台向乐心医疗提问："请问截至12月31日公司股东人数多少？谢谢！" ...

Group 1 - The core stock price of Leksin Medical (300562) closed at 13.93 yuan on January 7, 2026, down by 1.42% with a turnover rate of 3.6% and a trading volume of 58,300 shares, amounting to a transaction value of 81.63 million yuan [1][2] - On January 7, the net outflow of main funds was 1.12 million yuan, while the net inflow of speculative funds was 3.60 million yuan, and the net outflow of retail funds was 2.48 million yuan [2] Group 2 - Leksin Medical announced the use of idle raised funds totaling 129 million yuan to purchase principal-protected floating income structured deposits, which are linked to the AUD/USD exchange rate, with a term until April 15, 2026, and an expected annual yield of 0.50% to 1.80% [1][2] - The company has completed the necessary approval procedures from the board of directors, supervisory board, and shareholders' meeting for this investment, ensuring that the use of raised funds remains unaffected [1] - The company has implemented multiple measures to control investment risks, including tracking project progress, internal audit supervision, and information disclosure [1]

乐心医疗 2026 年公告 证券代码：300562 证券简称：乐心医疗 公告编号：2026-002 广东乐心医疗电子股份有限公司 关于使用闲置募集资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 广东乐心医疗电子股份有限公司（以下简称"公司"）于 2025 年 3 月 27 日召开的第四届董事会第二十二次会议、第四届监事会第十九次会议以及 2025 年 4 月 18 日召开的 2024 年年度股东大会审议通过了《关于使用闲置募集资金进 行现金管理的议案》，同意公司使用额度不超过人民币 18,000 万元的闲置募集 资金购买安全性高、流动性好、有保本约定的商业银行的理财产品，期限自公司 股东大会审议通过之日起 12 个月内有效，在该额度内，资金可以滚动使用。相 关内容详见公司 2025 年 3 月 29 日及 2025 年 4 月 18 日刊载于巨潮资讯网 （www.cninfo.com.cn）的相关公告。 根据上述决议，公司近日在广发银行股份有限公司（以下简称"广发银行"） 办理了使用部分闲置募集资金进行现金管理的相关业务，现就具体情 ...

Core Insights - LeXin Medical has received notification from the Guangdong Provincial Drug Administration regarding the acceptance of its application for the registration of electronic blood pressure monitors [2] - The registration change application for the electronic blood pressure monitor has been approved [2] Company Developments - The company has successfully navigated the regulatory process for its electronic blood pressure monitor, indicating progress in its product development and market readiness [2] - The approval of the registration change may enhance the company's product offerings and competitive position in the medical device market [2]

证券代码：300562 证券简称：乐心医疗 公告编号：2026-001 广东乐心医疗电子股份有限公司 关于申报医疗器械注册证获得受理 及完成医疗器械注册证变更的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 广东乐心医疗电子股份有限公司（以下简称"公司"）近日收到广东省药品 监督管理局的通知，获悉公司申请的电子血压计医疗器械注册事项已获受理、申 请的电子血压计医疗器械注册变更事项已通过审批，现将相关内容公告如下： 上述电子血压计均由主机、袖带、充电线（选配）组成，通过示波法测量成 人的收缩压、舒张压及脉率，所测数据通过液晶显示屏显示，测量数值可供诊断 参考。其中型号为"TMB-2275-B、TMB-2271-B、TMB-2271-BK、TMB-1776-BZY" 的电子血压计具备蓝牙功能，可实现血压测量数据实时传输（即测即传），方便 用户及时查看健康状况。 乐心医疗 2026 年公告 产品 名称 申请 事项 受理号 分类 型号 结构及组成 适用范围 电子血 压计 第二类医 疗器械注 册证核发 0010600120251142 II 类 TMB-2275- ...